Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes

Journal of Diabetes & Metabolism
doi 10.4172/2155-6156.1000200
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group


Related search